[HTML][HTML] Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma

J Lv, L Guo, JJ Liu, HP Zhao, J Zhang… - World journal of …, 2019 - ncbi.nlm.nih.gov
The incidence of esophageal adenocarcinoma (EAC) has increased in recent decades, and
its 5-year survival rate is less than 20%. As a well-established precursor, patients with …

DPP-4 inhibition and the path to clinical proof

B Ahrén - Frontiers in endocrinology, 2019 - frontiersin.org
In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates
the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent …

Evaluation of the cascade of diabetes care in the United States, 2005-2016

P Kazemian, FM Shebl, N McCann… - JAMA internal …, 2019 - jamanetwork.com
Importance Treatment advances in diabetes can meaningfully improve outcomes only if they
effectively reach the populations at risk. Objectives To evaluate whether the cascade of US …

2-Phenethylamines in medicinal chemistry: A review

CT Nieto, A Manchado, L Belda, D Diez, NM Garrido - Molecules, 2023 - mdpi.com
A concise review covering updated presence and role of 2-phenethylamines in medicinal
chemistry is presented. Open-chain, flexible alicyclic amine derivatives of this motif are …

[HTML][HTML] New advances of adiponectin in regulating obesity and related metabolic syndromes

Y Han, Q Sun, W Chen, Y Gao, J Ye, Y Chen… - Journal of …, 2024 - Elsevier
Obesity and related metabolic syndromes have been recognized as important disease risks,
in which the role of adipokines cannot be ignored. Adiponectin (ADP) is one of the key …

Role of dipeptidyl peptidase-4 (DPP4) on COVID-19 physiopathology

A Sebastián-Martín, BG Sánchez, JM Mora-Rodríguez… - Biomedicines, 2022 - mdpi.com
DPP4/CD26 is a single-pass transmembrane protein with multiple functions on glycemic
control, cell migration and proliferation, and the immune system, among others. It has …

Do we know the true mechanism of action of the DPP‐4 inhibitors?

ES Andersen, CF Deacon… - Diabetes, Obesity and …, 2018 - Wiley Online Library
The prevalence of type 2 diabetes is increasing, which is alarming because of its serious
complications. Anti‐diabetic treatment aims to control glucose homeostasis as tightly as …

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized …

J Rosenstock, V Perkovic, JH Alexander… - Cardiovascular …, 2018 - Springer
Background Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have
underrepresented patients with chronic kidney disease (CKD), leading to uncertainty …

A review upon medicinal perspective and designing rationale of DPP-4 inhibitors

S Kumar, A Mittal, A Mittal - Bioorganic & Medicinal Chemistry, 2021 - Elsevier
Abstract Type 2 Diabetes Mellitus (T2DM) is one of the highly prevalence disorder and
increasing day by day worldwidely. T2DM is a metabolic disorder, which is characterized by …

Adiponectin: The potential regulator and therapeutic target of obesity and Alzheimer's disease

JY Kim, S Barua, YJ Jeong, JE Lee - International journal of molecular …, 2020 - mdpi.com
Animal and human mechanistic studies have consistently shown an association between
obesity and Alzheimer's disease (AD). AD, a degenerative brain disease, is the most …